HRA has established the Treatment Equity project to advocate for changes to the Opioid Treatment Program (OTP) to ensure a modern, accessible and person-centred program for all service users. Treatment Equity is an ongoing program of work and priority area for HRA. See below for information on the work we are doing and drop back regularly for updates…
Breaking News!!!
SUBLOCADE® Being Withdrawn from the Australian Market…
BEING WITHDRAWN
Indivior (the pharmaceutical company who manufacturers and distributes Sublocade® (buprenorphine modified release solution for injection) has formally notified that they will be withdrawing Sublocade® from the Australian market.
According to the company, the timeframe for the planned discontinuation is that SUBLOCADE® will continue to be available until the planned date of last supply: 11 December 2026. Existing stock will remain available, and PBS claims may continue to be made for SUBLOCADE® in accordance with PBS arrangements until 31 December 2026.
The company further stated that the lead-in timeframe is designed to allow treating clinicians sufficient time to review ongoing treatment needs with people currently on Sublocade® treatment and consider appropriate management options, based on each person’s clinical circumstances.
Information provided to HRA by Indivior further states that:
“This planned discontinuation reflects operational and commercial considerations and is not related to any new safety, efficacy or quality concern identified for SUBLOCADE®.”
HRA will continue to provide updates on this important development as information becomes available. At HRA we understand that this information may be extremely distressing for people currently on Sublocade® treatment.
To this end, we are working alongside other key organisations (including AIVL) to support the development of timely, accessible information for OTP service users and their families, as well as, clinicians, prescribers, pharmacists and allied services in within the sector. We are also aware that state & territory health departments are also working to respond to this issue and the questions it raises for OTP service users and other key stakeholders.
If you live in NSW, you may find the following information produced by NSW Health useful: https://www.health.nsw.gov.au/aod/professionals/Pages/sublocade-discontinuation.aspx
As soon as additional information and resources are available, HRA will upload them via our website and social media channels. Come back regularly for updates and be sure to follow us on social media for the latest information as it becomes available…
Treatment Equity Project Update (May – June 2026)…
HRA has been doing a lot of work in the OTP space across May and June including being involved in the planning and organising of the upcoming National Consensus for Action Forum: A Roundtable on Australian Opioid Dependence Treatment being held in Canberra on 7 September at Parliament House.
Despite recent reforms to the payment architecture for OTP medicines, significant system-level challenges continue to affect how ODTP is delivered and experienced across Australia. Key issues, as identified in HRA’s recent OTP Policy Brief: ‘Reforming Australia’s Opioid Treatment Program – Investing in Access, Equity & Sustainability’ (see below) include access, workforce shortages, lack of contemporary clinical guidelines and ongoing stigma and discrimination.
In this context, the Canberra forum will bring together a diverse range of stakeholders, including consumer and community organisations, people with lived experience of ODTP, clinicians and professional bodies, researchers, and government representatives and funders to form consensus on how to progress change in this important area of health. The forum aims to identify shared national priorities to improve access, quality, consistency, and resourcing of ODTP across Australia and will culminate in the development of an advocacy statement articulating a shared national vision for ODTP reform, including priority actions for governments and key stakeholders.
The event will be invitation only (due to space restrictions) with invitations going out in early July. The event will be an in-person event but interested stakeholders will be able to watch proceedings (without participation) online. For more information about the forum and attending as an online observer, contact us via the details on our contacts page.
HRA Pre-Forum Webinar
To support the Canberra forum, HRA will be holding one of three pre-forum webinars designed to allow a broader range of stakeholders, than can attend the invitation only event, to have input into the development of the consensus advocacy statement that will be the outcome of the Canberra event. The HRA webinar will be held at 1 – 3pm (AEST) on Tuesday 10 August 2026. Further details on the webinar including registration information, speaker details, etc., will be posted on the HRA website and socials very soon, so please check back and make sure you are following us on your preferred social media platforms, so you don’t miss any information. We’d love to see you there!
Along with HRA webinar, two other webinars will be held in the lead-up to the Canberra forum: one focused on ODTP consumer perspectives being held by AIVL (https://aivl.org.au/) and a third and final webinar focused on ODTP clinical governance and research being held by MARC (https://www.monash.edu/medicine/ehcs/marc/home) for further information on these webinars contact AIVL and MARC directly.
Treatment Equity Project Update (April 2026)…
National OTP Advocacy Event (Sept 2026)
After the successful launch of HRA’s OTP Policy Brief in December last year (for more information see below), HRA has continued to advance the core goals of our Treatment Equity Project through ongoing collaborations with other key stakeholders in the OTP space. This work includes joining with many others to plan and organise an upcoming national OTP advocacy event to be held in Canberra in early September 2026. HRA is part of the advisory group for the event which is being led by the ACT peer-based drug user organisation, the Canberra Alliance for Harm Minimisation & Advocacy (CAHMA) and supported by the Australasian Professional Society for Alcohol & Other Drugs (APSAD). HRA is pleased that our recently released OTP Policy Brief and its targeted recommendations, will be used to inform the event including shaping the key advocacy/policy asks to government. For those who are interested in the event, we will be sure to post further details as soon as they become available – watch this space…
Joint RACP/AChAM OTP Advocacy
The first few months of 2026 have also seen the establishment of a new advocacy collaboration between HRA and the Royal Australasian College of Physicians (RACP) which includes the Australasian Chapter of Addiction Medicine (AChAM). HRA Executive Director, Dr Annie Madden AO and HRA Board member, Dr Richard Di Natale have been meeting regularly with key representatives of the RACP/AChAM to discuss and progress mutual advocacy priorities in relation to the Opioid Treatment Program in Australia. Although this collaboration is still in the early stages, work is already underway on advocacy towards revising and updating the National OTP Clinical Guidelines (which have not been updated since 2014), joint participation in the OTP Advocacy Event being planned for Sept 2026 in Canberra (above) and discussing opportunities to involve other relevant colleges and organisations in our advocacy work in the future.
AJGP Article on Stigma in OTP
HRA is also pleased to announce that HRA Executive Director, Dr Annie Madden AO has been invited to co-author an article with Dr Hester Wilson and two other colleagues, on the important topic of ‘Stigma for patients using alcohol & other drugs’ for the flagship publication of the Royal Australasian College of General Practice (RACGP), the Australian Journal of General Practice (AJGP). The article is currently in development and will be shared here once published. This new article will build on a piece originally published by Dr Wilson on this topic in March 2020 on ‘How Stigmatising Language Affects People Who Use Tobacco, Alcohol & Other Drugs’ which you can read here: https://www1.racgp.org.au/ajgp/2020/march/how-stigmatising-language-affects-people-in-austra
OTP Policy Brief
On 1 December 2025, HRA launched its new Opioid Treatment Program (OTP) Policy Brief: ‘Reforming Australia’s Opioid Treatment Program – Investing in Access, Equity & Sustainability’.
Australia’s Opioid Treatment Program (OTP) is a critical, evidence-based response to opioid dependence, that provides access to life-saving pharmacotherapy medications. HRA’s new Opioid Treatment Program Policy Brief outlines some of the key challenges facing the OTP in Australia and provides a series of evidence-based recommendations for creating a more responsive, accessible and sustainable OTP into the future.
Read our latest opinion piece on OTP reform…
To support the launch of our OTP Policy Brief on 2 December 2025, HRA published an opinion piece in Bio-Pharma Dispatch which speaks to HRA’s goals in developing the policy brief and steps out some of the most urgent reforms for the OTP in Australia in 2025. You can find the opinion piece: ‘Reforming Australia’s Opioid Dependence Treatment Program – From Red Tape to Person-Centred Care: https://pharmadispatch.com/news/reforming-australias-opioid-dependence-treatment-program-from-red-tape-to-person-centred-care
Breaking News…
There have been some recent reforms at the federal level to the Health Legislation Amendment (Removal of Requirement for a Collaborative Arrangement) Bill 2024 that have important implications for the ODT Program in Australia.
In May 2024, the legal requirement for Nurse Practitioners (NPs) and eligible midwives to be part of a ‘collaborative arrangement’ with a medical practitioner to provide certain subsidised services to patients was removed.
From 1 November 2024, NPs and eligible midwives can provide services subsidised by the MBS and prescribe certain medicines on the PBS without the need for a collaborative arrangement with a medical practitioner.
Harm Reduction Australia has been advocating for some time that NPs could be playing a much greater role in the delivery of ODT in Australia especially in regional and rural areas (but also metro and greater metro areas) where attracting and retaining GPs can be very challenging. We believe, these recent reforms remove some of the major barriers to this occurring.
HRA will continue to work with key stakeholders, through our Treatment Equity Project to make the most of this reform including how it might dovetail with last year’s PBS reforms (aka the ‘affordability reforms’) to create an even more accessible ODTP in Australia.
Deep Dive on OTP
As part of the HRA 2024 National Harm Reduction Forum in August, we ran a series of ‘deep dives’ on key areas of priority for HRA. One of these deep dives focused on the Opioid Treatment Program and aimed to bring together key voices in the OTP space to discuss the current state of opioid treatment in Australia and to identify areas of reform and how to achieve change. It was a packed online forum with great discussion and audience questions, but unfortunately, as it was a breakout session in Zoom, we were unable to record the session, we can, however, provide an outline of our speakers/panellists:
Moderator: Annie Madden, HRA Executive Director
Panellists:
- Sarah Lord (PAMS/HRVic)
- Adam Searby (Drug & Alcohol Nurses Association – DANA)
- Donna Searles (Nurse Practitioner/Qld Prisons Health)
- Charles Henderson (Burnet Institute)
- Prof. Suzie Nielsen (Monash Addiction Research Centre)
- Brett Valance (Nurse Practitioner, Regional Victoria)
- Dr. Hester Wilson (GP/Addiction Medicine Specialist/RACGP)
Rapporteur: Dr Jake Rance (HRA Board member and senior researcher at CSRH, UNSW)
PBS Reforms
Across 2021 – 2023, HRA strongly advocated for the Australian Government to remove the financial discrimination within the PBS against people on OTP as a matter of urgency. On 1 July 2023, ground-breaking changes came into effect which meant for the first time, OTP medications (methadone and buprenorphine) were listed on the Pharmaceutical Benefits Scheme (PBS), capping the consumer co-payment for OTP service users and ensuring that people on OTP pay the same as other Australians to access their OTP medications.
In the lead-up to 1 July 2023, HRA produced infographics and fact sheets to assist service users and others to understand the impact of the changes. These resources are provided below along with other relevant information related to the reforms…
PBS Reform Fact Sheets
Additional information
Federal and NSW Government ODT PBS reform information and fact sheets
- Federal Government:
Federal Government ODT reform information and fact sheets
- NSW Government:
Treatment Equity Communiques
During an advocacy campaign to remove the discriminatory, private, daily dispensing fees that OTP service users have been forced to pay for decades, Treatment Equity produced a series of communiques aimed at keeping our stakeholders up-to-date on developments. You can read these here:
Treatment Equity Communique #1
Treatment Equity Communique #2
Treatment Equity Communique #3